These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12648472)

  • 1. Mechanism of action of erbB tyrosine kinase inhibitors.
    Fry DW
    Exp Cell Res; 2003 Mar; 284(1):131-9. PubMed ID: 12648472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
    Anderson NG; Ahmad T
    Front Biosci; 2002 Sep; 7():d1926-40. PubMed ID: 12161338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
    Morin MJ
    Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance.
    Busse D; Yakes FM; Lenferink AE; Arteaga CL
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):47-55. PubMed ID: 11706396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibitors of the class 1 receptor tyrosine kinase family.
    Cockerill GS; Lackey KE
    Curr Top Med Chem; 2002 Sep; 2(9):1001-10. PubMed ID: 12171567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cancer with small-molecular-weight kinase inhibitors.
    Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
    Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERBB receptors and cancer: the complexity of targeted inhibitors.
    Hynes NE; Lane HA
    Nat Rev Cancer; 2005 May; 5(5):341-54. PubMed ID: 15864276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of tyrosine kinase.
    Klohs WD; Fry DW; Kraker AJ
    Curr Opin Oncol; 1997 Nov; 9(6):562-8. PubMed ID: 9370078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases.
    García-Echeverría C; Fabbro D
    Mini Rev Med Chem; 2004 Mar; 4(3):273-83. PubMed ID: 15032674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forthcoming receptor tyrosine kinase inhibitors.
    Choong NW; Cohen EE
    Expert Opin Ther Targets; 2006 Dec; 10(6):793-7. PubMed ID: 17105367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer].
    Campone M; Kerbrat P; Roché H; Bennouna J; Cuillière JC; Le Mevel B; Fumoleau P
    Bull Cancer; 2003 Oct; 90(10):851-64. PubMed ID: 14706914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.
    Fry DW
    Anticancer Drug Des; 2000 Feb; 15(1):3-16. PubMed ID: 10888032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ErbB-targeted therapeutic approaches in human cancer.
    Arteaga CL
    Exp Cell Res; 2003 Mar; 284(1):122-30. PubMed ID: 12648471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase, aurora kinase and leucine aminopeptidase as attractive drug targets in anticancer therapy - characterisation of their inhibitors.
    Ziemska J; Solecka J
    Rocz Panstw Zakl Hig; 2016; 67(4):329-342. PubMed ID: 27922739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tyrosine kinase receptor-ras-ERK signal transduction pathway as therapeutic tarfet in cancer].
    Leirdal M; Sioud M
    Tidsskr Nor Laegeforen; 2002 Jan; 122(2):178-82. PubMed ID: 11873574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting receptor tyrosine kinases in solid tumors.
    Zhang J; Hochwald SN
    Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.